Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland.
Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland.
J Immunol. 2024 Jul 1;213(1):75-85. doi: 10.4049/jimmunol.2300658.
In chronic obstructive pulmonary disease (COPD), inflammation gives rise to protease-mediated degradation of the key extracellular matrix protein, elastin, which causes irreversible loss of pulmonary function. Intervention against proteolysis has met with limited success in COPD, due in part to our incomplete understanding of the mechanisms that underlie disease pathogenesis. Peptidyl arginine deiminase (PAD) enzymes are a known modifier of proteolytic susceptibility, but their involvement in COPD in the lungs of affected individuals is underexplored. In this study, we showed that enzyme isotypes PAD2 and PAD4 are present in primary granules of neutrophils and that cells from people with COPD release increased levels of PADs when compared with neutrophils of healthy control subjects. By examining bronchoalveolar lavage and lung tissue samples of patients with COPD or matched smoking and nonsmoking counterparts with normal lung function, we reveal that COPD presents with markedly increased airway concentrations of PADs. Ex vivo, we established citrullinated elastin in the peripheral airways of people with COPD, and in vitro, elastin citrullination significantly enhanced its proteolytic degradation by serine and matrix metalloproteinases, including neutrophil elastase and matrix metalloprotease-12, respectively. These results provide a mechanism by which neutrophil-released PADs affect lung function decline, indicating promise for the future development of PAD-based therapeutics for preserving lung function in patients with COPD.
在慢性阻塞性肺疾病(COPD)中,炎症导致蛋白酶介导的关键细胞外基质蛋白弹性蛋白降解,从而导致肺功能不可逆转的丧失。针对蛋白酶解的干预在 COPD 中的效果有限,部分原因是我们对疾病发病机制的基础机制理解不完整。肽基精氨酸脱亚氨酶(PAD)酶是已知的蛋白酶解易感性调节剂,但它们在 COPD 患者肺部中的参与程度尚未得到充分探索。在这项研究中,我们表明酶同工型 PAD2 和 PAD4 存在于中性粒细胞的初级颗粒中,并且与健康对照受试者的中性粒细胞相比,COPD 患者的细胞释放出更高水平的 PAD。通过检查 COPD 患者、匹配的吸烟和不吸烟的肺功能正常的对照者的支气管肺泡灌洗液和肺组织样本,我们揭示 COPD 表现出明显增加的气道 PAD 浓度。在体外,我们在 COPD 患者的外周气道中建立了瓜氨酸化弹性蛋白,并且弹性蛋白瓜氨酸化显著增强了丝氨酸和基质金属蛋白酶(包括中性粒细胞弹性蛋白酶和基质金属蛋白酶-12)对其的蛋白水解降解。这些结果提供了一种机制,即中性粒细胞释放的 PAD 影响肺功能下降,表明基于 PAD 的治疗方法在未来有希望用于保护 COPD 患者的肺功能。